A retrospective analysis of patients with advanced renal cell carcinoma treated with temsirolimus
- Author:
Christina Ng
- Publication Type:Journal Article
- Keywords:
temsirolimus, metastatic renal cell carcinoma, adverse events
- MeSH:
Clear-cell metastatic renal cell carcinoma
- From:Journal of University of Malaya Medical Centre
2010;13(1):19-23
- CountryMalaysia
- Language:English
-
Abstract:
The clinical experience of the novel drug temsirolimus on eight patients with metastatic renal cell
carcinoma and who were refractory to other forms of treatment is reported. Although none of the
patients showed complete or partial response, three patients had stable disease. One patient was
prematurely withdrawn due to pneumonitis. Five patients died during the period of observation
of twenty months and the median survival time from start of treatment was ten months. Three
patients showed no evidence of adverse events (AE). Five patients showed dyslipidemia and two
had pneumonitis for which, the drug had to be withdrawn in one of them. None had significant
leucopenia. We conclude that temsirolimus has activity even in heavily pretreated patients in
advanced renal cell carcinoma and in addition, has the benefits of ease of administration and
good tolerability.
- Full text:P020160118599287938349.pdf
